---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091407"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:45:34.101259+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zura Bio reports Q2 2023 cash of $112.8M; advancing ZB-106 to Phase 2 in 2H 2024

## Summary
- Cash and equivalents $112.8M at June 30, 2023, up from $1.6M at Dec 31, 2022; sufficient to fund operations through 2026.
- R&D expenses $28.2M in Q2 2023 vs $0.1M in Q2 2022, driven by ZB-106 license from Eli Lilly.
- G&A expenses $5.7M in Q2 2023 vs $0.8M in Q2 2022, due to higher compensation and legal/accounting costs.
- Pipeline: ZB-106 Phase 2 trials for systemic sclerosis and hidradenitis suppurativa expected to start in 2H 2024; ZB-168 and ZB-880 Phase 2 trials in 2024.
- Completed ~$80M private placement in June 2023; joined Russell 2000/3000 indexes.

## SEC filing metadata
- accession: 0001104659-23-091407
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/0001104659-23-091407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/tm2323743d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091407
- JSON: https://secwatch.observer/filing/0001104659-23-091407.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091407.txt

## Key facts
- Earnings Releases
  Zura Bio Ltd reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: Zura Bio Limited (the “Company”) issued a press release announcing its second quarter 2023 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/0001104659-23-091407-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.